Informação sobre produto
DPM-1001 is a novel, orally available tyrosine phosphatase inhibitor. DPM-1001 prevents the activation of protein phosphatases by inhibiting the enzyme responsible for removing phosphate groups from tyrosine residues. This leads to an accumulation of insulin receptor substrate 1 (IRS1) in cells, which is associated with type 2 diabetes and other metabolic diseases. In addition, DPM-1001 has been shown to inhibit cancer growth in vitro and in vivo, as well as to prevent neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The chemical structure of DPM-1001 is apigenin linked through a phosphate group to a quinoline moiety. The symptoms of DPM-1001 overdose are nausea, vomiting, diarrhea, abdominal pain, dizziness and headache.
Propriedades químicas
Consulta técnica sobre: 3D-WIC17227 DPM-1001
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
